Low-Dose IL-2 T Cell Therapy for Cancer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current T cell therapies face challenges with short survival and function of transferred T cells, and high doses of IL-2 can induce toxicity and expand regulatory T cell populations, reducing therapy efficacy.

Innovation Solution

Administering a low dose of IL-2, less than 2.0 MIU/m2/day, in combination with T cell therapy to reduce toxicity and side effects while maintaining therapeutic outcomes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If high doses of IL-2 are administered to extend T cell lifespan and function, then T cell survival is improved, but toxicity and side effects increase

Engineering Contradiction:

ImproveT cell survivalVSAvoidtoxicity

Core Design Contradiction:

Duration of action of moving objectVSObject-affected harmful factors

Solution Approach 1:

The patent changes the dosage parameter of IL-2 from conventional high doses to a specific low dose range (0.1-2.0 MIU/m2/day), which fundamentally alters the biological effect profile. This parameter change allows IL-2 to selectively support transferred T cells without inducing the toxicities and regulatory T cell expansion associated with high doses, thereby resolving the contradiction between extending T cell survival and avoiding harmful effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If high doses of IL-2 are administered to enhance T cell function, then T cell efficacy is improved, but regulatory T cell expansion increases reducing therapy efficacy

Engineering Contradiction:

ImproveT cell therapy efficacyVSAvoidregulatory T cell expansion

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

By changing the IL-2 dosage parameter to a low dose range (0.1-2.0 MIU/m2/day), the patent creates a selective environment that favors the survival and function of transferred antigen-specific T cells while preventing the expansion of regulatory T cells. This parameter change resolves the contradiction by decoupling the beneficial effects on therapeutic T cells from the harmful effects of regulatory T cell expansion that occur at high doses

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20230226110A1T cell therapy

Publication Date: 2023.07.20 ACHILLES THERAPEUTICS UK LTD

AI summary

The present invention relates to a method of treating cancer in a patient, comprising administering to the patient a T cell therapy and a dose of IL-2 of less than about 2.0 MIU/m2/day.